CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new antiviral drugs for HIV-1 by targeting essential cellular proteins involved in the virus's replication process. By focusing on co-factors like Lens Epithelium Derived Growth Factor, the goal is to create more effective and affordable treatments, particularly for patients in sub-Saharan…
Standard therapy of infection with the human immunodeficiency virus type 1 (HIV-1) is based on potent cocktails of drugs targeting viral proteins.
This treatment is associated with severe side effects and is almost unaffordable for the patients living in sub-Saharan Africa.
Incomplete suppression of HIV replication results in drug-resistance.
Therefore, a continued research effort is required to develop more potent, cheaper and less toxic antivirals.
The insight has grown that HIV requires cellu…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Pisa
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Siena
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Messina
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Ireland, LITTLE ISLAND - CORK
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
